Results 241 to 250 of about 123,621 (353)

UK Medical Cannabis Registry: A clinical outcomes analysis for insomnia. [PDF]

PLOS Ment Health
Aggarwal A, Erridge S, Cowley I, Evans L, Varadpande M, Clarke E, McLachlan K, Coomber R, Rucker JJ, Weatherall MW, Sodergren MH.   +10 more
europepmc   +1 more source

Data Sheet 4_19 patients report seizure freedom with medical cannabis oil treatment for drug-resistant epilepsy: a case series.docx

Frank Yizhao Chen (21383288), Joshua Myles Duckman (21383291), Brenden Samuel Rabinovitch (21383294), Katrin Julia Hannesson (21383297), Evan Cole Lewis (16304961)   +4 more
openalex   +1 more source

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology

British Journal of Pharmacology, EarlyView.
Theorized mechanism of dopamine homeostasis restoration in the nucleus accumbens core induced by a psychedelic intervention. Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive ...
Lucas Wittenkeller, Gary Gudelsky, T. John Winhusen, Davide Amato   +3 more
wiley   +1 more source

Medical cannabis for the treatment of insomnia. [PDF]

Cochrane Database Syst Rev
Varela LB, Escobar Liquitay CM, Díaz Menai S, Garegnani L.   +3 more
europepmc   +1 more source

Supplementary Material for: Factors Associated with Possible Cannabis Use Disorder among Adults Using Medical Cannabis in Florida: A Cross-sectional Study

figshare admin karger, Cook Rl, Maloney S., Gao H., Gracy A., Sajdeya R., Sivarupan M., Hasan M.M., Jury H., Wang Y.   +9 more
openalex   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Development and Implementation of a Medical Cannabis Clinic Within a Geriatrics Primary Care Clinic: Preliminary Data. [PDF]

J Am Geriatr Soc
Weaver R, Velez B, Weissberger ML, Zimmerman KM.   +3 more
europepmc   +1 more source

Evidence-based Approach Using Multivariate Regression Analysis And Machine Learning Algorithms To Discover Optimum Medical Cannabis Compound Ratios For Highest Efficacy And Lowest Side-effects In PTSD Subjects

, 2017
Seth Kutty, Christina Cheney, Abhiraj Malappa, Xijun Zhang, Sathvik Raju, Rajesh Sundaram, Lakshman Kolasani, Sharath Kalkur   +7 more
openalex   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

UK Medical Cannabis Registry: An Analysis of Outcomes of Medical Cannabis Therapy for Hypermobility-Associated Chronic Pain. [PDF]

ACR Open Rheumatol
Dickinson M, Erridge S, Warner-Levy J, Clarke E, McLachlan K, Coomber R, Holden W, Rucker JJ, Platt MW, Sodergren MH.   +9 more
europepmc   +1 more source